It was found that patients receiving combination regimens containing gemcitabine were more likely to have a higher incidence of neutropenia (RR = 1.33, 95% CI 1.25 to 1.42) (Figure 3A), thrombocytopenia (RR = 6.54, 95% CI 4.10 to 10.45) (Figure 3B), anemia (RR = 2.37, 95% CI 1.59 to 3.52) (Figure 3C), and an increased level of serum alanine aminotransferase (ALT) (RR = 2.22, 95% CI 1.34 to 3.69) (Figure 3D). This evidence concerns the gene GPT and anemia.